LumiraDx, a Next-Generation Point of Care Diagnostics Testing Company to List on Nasdaq via Merger with CA Healthcare Acquisition Corp

Published Apr 07 2021 at 5:00 AM GMT
Key
Points
  • LumiraDx's innovative diagnostic testing Platform has been in development since 2014 and is designed to offer a broad menu of tests with lab-comparable performance at a low cost and with results in less than 12 minutes at the point of care This transaction will drive LumiraDx's pipeline of 30+ assays across common health conditions including infectious disease, cardiovascular disease, diabetes, and coagulation disorders to address a $50+ billion global market opportunity with LumiraDx Platform Company to be.




Stats

  • Published Apr 7, 2021 5:00 AM GMT